健帆生物收盘上涨1.45%，滚动市盈率23.87倍，总市值172.90亿元

Company Overview - Jianfan Biological Technology Group Co., Ltd. specializes in the research, production, and sales of biomaterials and high-tech medical devices [2] - The main products include various blood purification devices and consumables, such as HA series blood perfusion devices and DX-10 blood purification machines [2] - The company has received multiple national recognitions, including being a key high-tech enterprise under the National Torch Program and a national technology innovation demonstration enterprise [2] Financial Performance - As of the first quarter of 2025, the company reported a revenue of 548 million yuan, a year-on-year decrease of 26.40% [2] - The net profit for the same period was 189 million yuan, down 33.71% year-on-year, with a gross profit margin of 80.74% [2] Market Position - The company's current price-to-earnings (PE) ratio is 23.87, significantly lower than the industry average of 49.11 and the industry median of 35.89 [1][3] - Jianfan Biological ranks 54th in terms of PE ratio within the medical device industry [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 52,502, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1]